Mbiine Ronald, Wayengera Misaki, Ocan Moses, Kiwanuka Noah, Munabi Ian, Muwonge Haruna, Lekuya Hervé Monka, Kawooya Ismael, Nakanwagi Cephas, Kinengyere Alison Annet, Joloba Moses, Galukande Moses
Makerere University College of Health Sciences Kampala, Uganda.
Center for Rapid Evidence Synthesis Kampala, Uganda.
Am J Stem Cells. 2022 Aug 20;11(4):56-63. eCollection 2022.
Autologous adipose-derived stromal vascular fraction (SVF) is an emerging therapy that is being pioneered as a potential treatment for keloids and hypertrophic scars. Up to this point, there isn't a cure for keloids and hypertrophic scars yet they comprise the commonest benign skin disorders. Despite published studies reporting potential therapeutic benefits of SVF, their use and efficacy on scar improvement are not clearly described. The aim of this review is to describe the clinical practice involved in harvesting, processing, utilization of SVF, and associated efficacy in scar treatment.
We shall include published clinical articles evaluating the efficacy of SVF on improving scar characteristics and assessment scores among adults with keloids or hypertrophic scars. Article search of Medline/PubMed, Cochrane Library and Embase using Mesh terms of "scars" and "stromal vascular fraction" combined with the Boolean operators ("AND", "OR") will be performed by two independent researchers following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement. The primary outcome measure will be the mean difference in the Scar characteristics including Scar assessment scores, scar thickness among others.
Descriptive data synthesis and mean differences between treatment arms will be calculated for the primary outcome of the scar assessment scores. In case more than three studies provide consistent characteristics of the scar assessment scores, a meta-analysis will be conducted.
Evidence obtained from the systematic review will form the foundation upon which further clinical trials research will be conducted in evaluating the efficacy of autologous adipose-derived stromal vascular fraction in keloid and hypertrophic scar. The systematic review has been submitted to the PROSPERO database and is currently under review.
自体脂肪来源的基质血管成分(SVF)是一种新兴的治疗方法,正被开拓用于瘢痕疙瘩和增生性瘢痕的潜在治疗。到目前为止,瘢痕疙瘩和增生性瘢痕尚无治愈方法,但它们却是最常见的良性皮肤疾病。尽管已发表的研究报告了SVF的潜在治疗益处,但其在改善瘢痕方面的应用和疗效尚未得到清晰描述。本综述的目的是描述SVF采集、处理、利用过程中的临床实践以及在瘢痕治疗中的相关疗效。
我们将纳入已发表的临床文章,这些文章评估了SVF对改善瘢痕疙瘩或增生性瘢痕成人患者的瘢痕特征和评估分数的疗效。两名独立研究人员将按照系统评价和Meta分析方案的首选报告项目(PRISMA-P)声明,使用“瘢痕”和“基质血管成分”的医学主题词,并结合布尔运算符(“AND”、“OR”)在Medline/PubMed、Cochrane图书馆和Embase中进行文章检索。主要结局指标将是瘢痕特征的平均差异,包括瘢痕评估分数、瘢痕厚度等。
将计算治疗组之间瘢痕评估分数主要结局的描述性数据合成和平均差异。如果有超过三项研究提供了瘢痕评估分数的一致特征,将进行Meta分析。
从系统评价中获得的证据将为进一步开展临床试验研究评估自体脂肪来源的基质血管成分在瘢痕疙瘩和增生性瘢痕治疗中的疗效奠定基础。该系统评价已提交至PROSPERO数据库,目前正在审核中。